Ready But Waiting: Medicare Carrier Will Withhold Avastin Coverage Changes Pending Possible FDA Hearing
This article was originally published in The Pink Sheet Daily
Large Medicare claims contractor Palmetto GBA has decided to hold on revising its Medicare Part B coverage policies for Avastin.
You may also be interested in...
FDA's decision to withdraw approval of Roche/Genentech's Avastin for first-line metastatic breast cancer is proving to be an unpopular action, though the ramifications are not yet clear.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.